Buy Mabtas : Rituximab 100 mg/10 ml Injection Online

Description

Product Overview: Mabtas is a potent therapeutic formulation containing 100 mg of Rituximab per 10 ml injection, meticulously manufactured by Intas Pharmaceuticals. Rituximab, the active ingredient in Mabtas, is a monoclonal antibody that targets specific proteins on cancerous B-cells, thereby aiding in the treatment of various autoimmune diseases and certain types of cancer.

Key Features:

1. Active Ingredient: Mabtas contains Rituximab, a monoclonal antibody that selectively targets CD20-positive B-cells, thereby modulating the immune response and inhibiting the growth of cancerous cells.
2. Strength: Each Mabtas injection delivers 100 mg of Rituximab in a 10 ml solution, ensuring precise dosing for effective therapeutic outcomes.
3. Packaging: Mabtas is available in vials or pre-filled syringes, providing healthcare professionals with convenient options for administration.
4. Manufactured by Intas Pharmaceuticals: Mabtas is manufactured under stringent quality control measures by Intas Pharmaceuticals, a reputable pharmaceutical company known for its commitment to innovation and excellence in drug development and manufacturing.

Indications: Mabtas is indicated for the treatment of various medical conditions, including:

• Non-Hodgkin’s lymphoma (NHL)
• Chronic lymphocytic leukemia (CLL)
• Rheumatoid arthritis (RA)
• Granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis)
• Microscopic polyangiitis (MPA)

Administration: Mabtas is typically administered intravenously (IV) under the supervision of a qualified healthcare professional. The dosage and administration schedule may vary depending on the specific medical condition being treated and the patient’s individual response to therapy.

Storage: Mabtas injections should be stored at the recommended temperature, as specified in the product labeling, and protected from light. It is essential to follow the storage instructions provided by the manufacturer to maintain the stability and efficacy of the medication.

Precautions:

• Prior to initiating Mabtas therapy, patients should undergo thorough evaluation, including screening for infections and other medical conditions.
• Patients should be monitored closely during and after Mabtas infusion for signs of infusion reactions, including fever, chills, rash, and respiratory symptoms.
• Healthcare providers should exercise caution when administering Mabtas to patients with a history of cardiac or pulmonary conditions, as the medication may exacerbate these conditions.

Adverse Reactions: Common adverse reactions associated with Mabtas may include infusion-related reactions, infections, hematologic abnormalities, and gastrointestinal disturbances. Patients should report any new or worsening symptoms to their healthcare provider promptly.

Disclaimer: This description provides general information about Mabtas 100 mg/10 ml Injection manufactured by Intas Pharmaceuticals. It is not intended to replace professional medical advice or serve as a comprehensive guide. Patients should consult their healthcare provider for personalized guidance regarding the use of Mabtas or any other medication.